Consequently, the study of small-molecule drugs able to inhibit Piezo1 may pave the way for a potential pharmacological intervention to treat neurocognitive deficits or other neurological diseases associated with Piezo1 overexpression. This evidence concerns the gene PIEZO1 and nervous system disorder.